Does Botulinum Toxin Type A Interact with Rimabotulinumtoxinb?
CDI records a major classification for Botulinum Toxin Type A and Rimabotulinumtoxinb. The stored summary is: Concurrent or overlapping administration (within 4 months) may exacerbate excessive neuromuscular weakness and paralysis. The mechanism involves potentiation of neuromuscular paralysis. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Botulinum Toxin Type A Class
- Acetylcholine Release Inhibitor
- Rimabotulinumtoxinb Class
- Acetylcholine Release Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Potentiation of neuromuscular paralysis
What To Tell Your Doctor or Pharmacist
If you are taking Botulinum Toxin Type A and your doctor is considering prescribing Rimabotulinumtoxinb (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider